Blue Trust’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$937 Hold
3
– – ﹤0.01% 2181
2026
Q2
$948 Hold
3
– – ﹤0.01% 2303
2026
Q1
$599 Hold
3
– – ﹤0.01% 2321
2025
Q4
$567 Buy
+3
New +$576 ﹤0.01% 2372
2024
Q4
– Sell
-56
Closed -$4.72K – 2739
2024
Q3
$4.72K Buy
56
+37
+195% +$3.72K ﹤0.01% 2415
2024
Q2
$1.39K Buy
+19
New +$1.51K ﹤0.01% 2503
2024
Q1
– Sell
-5
Closed – – 2491
2023
Q4
$0 Buy
+5
New +$295 ﹤0.01% 2610

Other funds holding LGND

Blue Trust's LGND Position: Q3 2026 in Review

Blue Trust held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 3 shares worth $937. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Blue Trust first reported a position in LGND in Q4 2023 and has held it in 7 quarters since. The position peaked at $4.72K in Q3 2024. 359 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Blue Trust held 3 shares of Ligand Pharmaceuticals worth $937 as of Q3 2026.
  • Blue Trust left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2181 holding.
  • Blue Trust first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • Blue Trust's Ligand Pharmaceuticals position peaked at $4.72K in Q3 2024.
  • 359 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.